Cited by 686Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsGenetic factors in colorectal cancer

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

André, Thierry, de Gramont, Armand, Vernerey, Dewi, Chibaudel, Benoist, Bonnetain, Franck, Tijeras-Raballand, Annemilaï, Scriva, Aurelie, Hickish, Tamas, Tabernero, Josep, Van Laethem, Jean Luc, Banzi, Maria, Maartense, Eduard, Shmueli, Einat, Carlsson, Goran U., Scheithauer, Werner, Papamichael, Demetris, Möehler, Marcus, Landolfi, Stefania, Demetter, Pieter, Colote, Soudhir, Tournigand, Christophe, Louvet, Christophe, Duval, Alex, Fléjou, Jean-François, de Gramont, Aimery·2015·Journal of Clinical Oncology

DOI 10.1200/jco.2015.63.4238

Open this paper in CoChat — free account

Abstract

Purpose: The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation. Methods: Survival actualization after 10-year follow-up was performed in 2,246 patients with resected stage II to III colon cancer. We assessed MMR status and BRAF mutation in 1,008 formalin-fixed paraffin-embedded specimens. Results: After a median follow-up of 9.5 years, 10-year OS rates in the bolus/infusional fluorouracil plus leucovorin (LV5FU2) and LV5FU2 plus oxaliplatin (FOLFOX4) arms were 67.1% versus 71.7% (hazard ratio [HR], 0.85; P = .043) in the whole population, 79.5% versus 78.4% for stage II (HR, 1.00; P = .980), and 59.0% versus 67.1% for stage III (HR, 0.80; P = .016) disease. Ninety-five patients (9.4%) had MMR-deficient (dMMR) tumors, and 94 (10.4%) had BRAF mutation. BRAF mutation was not prognostic for OS (P = .965), but dMMR was an independent prognostic factor (HR, 2.02; 95% CI, 1.15 to 3.55; P = .014). HRs for DFS and OS benefit in the FOLFOX4 arm were 0.48 (95% CI, 0.20 to 1.12) and 0.41 (95% CI, 0.16 to 1.07), respectively, in patients with stage II to III dMMR and 0.50 (95% CI, 0.25 to 1.00) and 0.66 (95% CI, 0.31 to 1.42), respectively, in those with BRAF mutation. Conclusion: The OS benefit of oxaliplatin-based adjuvant chemotherapy, increasing over time and with the disease severity, was confirmed at 10 years in patients with stage II to III colon cancer. These updated results support the use of FOLFOX in patients with stage III disease, including those with dMMR or BRAF mutation.

Integrity signals

Registry

Crossref · 10.1200/jco.2015.63.4238

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Zaninelli, M., Clingan, P. R., Bridgewater, J. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,694
Self-citation
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
André, T., Boni, C., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Bonetti, A. V., Clingan, P. R., Bridgewater, J. A., Rivera, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6771 · Cited by 2,276
Self-citation
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J. A., McAllister, P. K., Cutsem, E. V., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.063 · Cited by 1,438
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Labianca, R., Nordlinger, B., Beretta, G. D., Mosconi, S., Mandalà, M., Cervantes, A. M. R., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt354 · Cited by 1,436
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,178
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07
Kuebler, J. P., Wieand, H. S., O’Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., Petrelli, N. J., Findlay, M. P. N., Seay, T. E., Atkins, J. N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2974 · Cited by 1,055

Flagged first, then by citations

Show all 32 references

Sorted by citations

Items 201–300 of 686

Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07
Kim, S. T., Kim, S. Y., Lee, J., Yun, S. H., Kim, H. C., Lee, W. Y., Kim, T. W., Hong, Y. S., Lim, S.-B., Baek, J. Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02962 · Cited by 21
Prognostic significance of KRAS, NRAS, BRAF, and PIK3CA mutations in stage II/III colorectal cancer: A retrospective study and meta-analysis
Kang, D., Li, J., Li, Y., Xu, J., Yang, J., & Zhang, Z. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320783 · Cited by 21
Recent advances in understanding colorectal cancer
Stintzing, S. (2018) · F1000Research · doi:10.12688/f1000research.14604.1 · Cited by 21
Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells
Gloria, H. C., Nogueira, L. J., Grudzinski, P. B., Ghignatti, P. V. D. C., Guecheva, T. N., Leguisamo, N. M., & Saffi, J. (2021) · BMC Cancer · doi:10.1186/s12885-021-08188-7 · Cited by 21
Personalizing Adjuvant Therapy for Stage II/III Colorectal Cancer
McCleary, N. J., Benson, A. B., & Dienstmann, R. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175660 · Cited by 21
Predicting 5-year recurrence risk in colorectal cancer: development and validation of a histology-based deep learning approach
Han, X. G., Weng, Z., Sun, K., Shen, J., Lin, J., Chen, S., Ли, Б., Shi, Y., Kuang, M., Song, X., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02573-2 · Cited by 24
Modified Banxiaxiexin decoction benefitted chemotherapy in treating gastric cancer by regulating multiple targets and pathways
Zhang, Z., Wu, C., Liu, N., Wang, Z., Pan, Z., Jiang, Y., Tian, J., & Sun, M. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118277 · Cited by 21
Polo-like kinase 2 promotes chemoresistance and predicts limited survival benefit from adjuvant chemotherapy in colorectal cancer
Xie, Y., Liu, Y., Li, Q., & Chen, J. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4328 · Cited by 22
Gastrointestinal toxic effects in patients with cancer receiving platinum-based therapy
Abu‐Sbeih, H., Mallepally, N., Goldstein, R. S., Chen, E., Tang, T., Dike, U. K., Alasadi, M., Westin, S. N., Halperin, D. M., & Wang, Y. (2020) · Journal of Cancer · doi:10.7150/jca.37777 · Cited by 21
Rhodium Complexes Targeting DNA Mismatches as a Basis for New Therapeutics in Cancers Deficient in Mismatch Repair
Nano, A., Dai, J., Bailis, J. M., & Barton, J. K. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00302 · Cited by 21
Tertiary lymphoid structures signature predicts prognosis and clinical benefits from neoadjuvant chemotherapy and PD-1 blockade in colorectal adenocarcinoma
Guo, Z., Feng, H., Jia, W., Zhang, T., Chen, M., Xu, Z., Zheng, F., Huang, C., Li, Z., Liu, K., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002568 · Cited by 20
Receipt of Adjuvant Chemotherapy in Stage II Colon Cancer and Overall Survival: A National Cancer Database Study
Enofe, N., Morris, A. D., Liu, Y., Liang, W., Wu, C. S.-Y., Sullivan, P. S., Balch, G. C., Staley, C. A., Gillespie, T. W., & Shaffer, V. O. (2020) · Journal of Surgical Research · doi:10.1016/j.jss.2020.02.016 · Cited by 20
Deep Learning Prediction of Metastasis in Locally Advanced Colon Cancer Using Binary Histologic Tumor Images
Schiele, S., Arndt, T. T., Martin, B., Miller, S., Bauer, S., Banner, B. M., Brendel, E.-M., Schenkirsch, G., Anthuber, M., Huss, R., et al. (2021) · Cancers · doi:10.3390/cancers13092074 · Cited by 22
Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer
Osumi, H., Shinozaki, E., & Yamaguchi, K. (2020) · Cancers · doi:10.3390/cancers12061566 · Cited by 21
Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford
Abrha, A., Shukla, N., Hodan, R., Longacre, T. A., Raghavan, S. S., Pritchard, C. C., Fisher, G. A., Ford, J. M., & Haraldsdóttir, S. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa054 · Cited by 20
Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm
Ryan, É. J., Creavin, B., & Sheahan, K. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01369 · Cited by 22
Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association
Salvatore, L., Imperatori, M., Arnoldi, E., Carnaghi, C., Cordio, S. S., Cosimelli, M., Cremolini, C., Maiello, E., Martinelli, E., Normanno, N., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-001001 · Cited by 21
Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival
Mendis, S. R., Beck, S., Lee, B., Lee, M., Wong, R., Kosmider, S., Shapiro, J. D., Yip, D., Steel, S. A., Nott, L. M., et al. (2019) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13135 · Cited by 20
Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials
Yin, J., Salem, M. E., Dixon, J. G., Jin, Z., Cohen, R., de Gramont, A., Cutsem, E. V., Taı̈eb, J., Alberts, S. R., Wolmark, N., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab187 · Cited by 19
Self-citation
Oxaliplatin‐induced increase in splenic volume; irreversible change after adjuvant FOLFOX
Iwai, T., Yamada, T., Koizumi, M., Shinji, S., Yokoyama, Y., Takahashi, G., Takeda, K., Hara, K., Ohta, K., & Uchida, E. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24756 · Cited by 19
MicroRNA-940 restricts the expression of metastasis-associated gene MACC1 and enhances the antitumor effect of Anlotinib on colorectal cancer
Wang, Y., Zhao, M., Zhao, H., Cheng, S., Bai, R., & Song, M. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s195364 · Cited by 19
Microsatellite instability as a unique characteristic of tumors and a predictor of response to immune therapy
Tryakin, A. A., Fedyanin, M. Y., Цуканов, А. С., Shelygin, Y. A., Покатаев, И. А., Ignatova, E., Хакимова, Г. Г., Frolova, M. A., & Tjulandin, S. (2020) · Malignant tumours · doi:10.18027/2224-5057-2019-9-4-59-69 · Cited by 19
Eligibility of Real-World Patients With Stage II and III Colon Cancer for Adjuvant Chemotherapy Trials
Batra, A., Kong, S., & Cheung, W. Y. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.05.005 · Cited by 19
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer
Chibaudel, B., Henriques, J., Rakez, M., Brenner, B., Kim, T. W., Martinez–Villacampa, M., Gallego-Plazas, J., Cervantes, A. M. R., Shim, K., Jonker, D. J., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.20425 · Cited by 20
Self-citation
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial
Petrelli, F., Rulli, E., Labianca, R., Lonardi, S., Rosati, G., Dotti, K. F., Ronzoni, M., Pella, N., Pusceddu, V., Banzi, M. C., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.477 · Cited by 21
Self-citation
A copper–platinum nanoplatform for synergistic photothermal and chemodynamic tumor therapy via ROS outburst and GSH exhaustion
Li, C., Jia, W., Guo, Z., Kang, Y. Q., Zhou, C., Zhao, R., Cheng, X., & Jia, N. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02288a · Cited by 19
SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023)
Pericay, C., Montagut, C. O., Reina, J. J., Melián, M., Alcaide, J., Tarazona, N., Ruiz‐Casado, A., González‐Flores, E., Graña, B., & Grávalos, C. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03559-5 · Cited by 22
A DNA methylation signature for the prediction of tumour recurrence in stage II colorectal cancer
Li, M., Zhu, C., Xue, Y., Miao, C., He, R., Li, W., Zhang, B., Yu, W., Huang, X., Lv, M., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02155-8 · Cited by 18
Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer
Makondi, P. T., Lee, C., Huang, C., Chu, C., Chang, Y., & Wei, P. (2018) · PLoS ONE · doi:10.1371/journal.pone.0189582 · Cited by 18
Role of circulating tumor DNA in the management of patients with colorectal cancer
Moati, É., Taly, V., Didelot, A., Perkins, G., Blons, H., Taı̈eb, J., Laurent‐Puig, P., & Zaanan, A. (2018) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2018.03.002 · Cited by 19
Mismatch Repair Deficiency Assessment by Immunohistochemistry: For Lynch Syndrome Screening and Beyond
Wong, H., Christie, M., Gately, L., Tie, J., Lee, B., Semira, C., Lok, S. W., Wong, R., & Gibbs, P. (2018) · Future Oncology · doi:10.2217/fon-2018-0319 · Cited by 18
Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
Chanzá, N. M., Tripathi, A., & Harshman, L. C. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0639-0 · Cited by 18
Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer
Batra, A., Rigo, R., Sheka, D., & Cheung, W. Y. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i6.604 · Cited by 20
Coptidis Rhizoma Extract Reverses 5-Fluorouracil Resistance in HCT116 Human Colorectal Cancer Cells via Modulation of Thymidylate Synthase
Kang, Y.-H., Lee, J., Lee, N., Kim, S., Seo, C., & Son, C. (2021) · Molecules · doi:10.3390/molecules26071856 · Cited by 18
Association of chemotherapy with survival in stage II colon cancer patients who received radical surgery: a retrospective cohort study
Lv, Z., Liang, Y., Liu, H., & Mo, D. (2021) · BMC Cancer · doi:10.1186/s12885-021-08057-3 · Cited by 17
Distinct clinical pattern of colorectal cancer patients with POLE mutations: A retrospective study on real-world data
Jiang, M., Jia, Y.-L., Han, J., Shi, J., Su, C., Zhang, R., Xing, M., Jin, S., & Zong, H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.963964 · Cited by 18
Chemotherapy induces immune checkpoint VISTA expression in tumor cells via HIF-2alpha
Li, N., Yang, S., Ren, Y. X., Tai, R., Liu, H., Wang, Y., Li, J., Wang, F., Xing, J., Zhang, Y., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115492 · Cited by 18
Development and validation of prediction models for the prognosis of colon cancer with lung metastases: a population-based cohort study
Ma, Z., Yang, S., Yang, Y., Luo, J., Zhou, Y., & Yang, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1073360 · Cited by 17
Prognostic Value of E-cadherin-, CD44-, and MSH2-associated Nomograms in Patients With Stage II and III Colorectal Cancer
Qu, J., Jiang, Y., Liu, H., Deng, H., Yu, J., Qi, X., Ge, W., & Li, G. (2017) · Translational Oncology · doi:10.1016/j.tranon.2016.12.005 · Cited by 17
Oncologic Effects of Primary Tumor-Sidedness on Patients with Stages 1–3 Colon Cancer: A Meta-Analysis
Ha, G. W., Kim, J. H., & Lee, M. R. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07164-7 · Cited by 17
Modeling oxaliplatin resistance in colorectal cancer reveals a SERPINE1-based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtype
Wong, S. Q. R., Das, M., Tenzin, K., Shirgaonkar, N., Chua, H., Chee, L. X., Yeoh, A. S., Murugiah, A. A., Chua, W. Y., Theardy, M. S., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07855-y · Cited by 16
High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer
Mohamed, A., Jiang, R., Philip, P. A., Diab, M., Behera, M., Wu, C. S.-Y., Alese, O. B., Shaib, W. L., Gaines, T. M., Balch, G. C., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.755113 · Cited by 16
Time‐dependent and nonlinear effects of prognostic factors in nonmetastatic colorectal cancer
Chi, S., Tian, Y., Li, J., Tong, D., Kong, X., Poston, G. J., Ding, K., & Li, J. (2017) · Cancer Medicine · doi:10.1002/cam4.1116 · Cited by 16
Precision medicine for adjuvant chemotherapy of resected colorectal cancer
Miyamoto, Y., Hiyoshi, Y., Sawayama, H., Tokunaga, R., & Baba, H. (2020) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12397 · Cited by 14
Microsatellite instability and chemosensitivity in solid tumours
Cherri, S., Oneda, E., Noventa, S., Melocchi, L., & Zaniboni, A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221099347 · Cited by 18
Effect of PRM1201 Combined With Adjuvant Chemotherapy on Preventing Recurrence and Metastasis of Stage III Colon Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Jia, R., Liu, N., Cai, G., Zhang, Y., Xiao, H., Zhou, L., Ji, Q., Zhao, L., Zeng, P., Liu, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.618793 · Cited by 16
Analysis of the Clinicopathological Characteristics of Stage I–III Colorectal Cancer Patients Deficient in Mismatch Repair Proteins
Liang, Y., Cai, X., Xu, Z., & Yin, H. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s278029 · Cited by 16
pT3 colorectal cancer revisited: a multicentric study on the histological depth of invasion in more than 1000 pT3 carcinomas—proposal for a new pT3a/pT3b subclassification
Foersch, S., Lang‐Schwarz, C., Eckstein, M., Geppert, C. I., Schmitt, M. P., Konukiewitz, B., Groll, T., Schicktanz, F., Engel, J., Gleitsmann, M., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01889-1 · Cited by 15
Guidance for Treating the Older Adults with Colorectal Cancer
Ioffe, D., & Dotan, E. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01071-6 · Cited by 15
Evaluating the Combination of Microsatellite Instability and Mutation in BRAF as Prognostic Factors for Patients With Colorectal Cancer
Sinicrope, F. A. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.06.038 · Cited by 15
Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future
Cohen, R., Shi, Q., & André, T. (2020) · Cancers · doi:10.3390/cancers12071990 · Cited by 18
Self-citation
The Optimal Duration of Adjuvant Chemotherapy in Colon Cancer
Collienne, M., & Arnold, D. (2020) · Cancers · doi:10.3390/cancers12092509 · Cited by 15
Translation of IDEA trial results into clinical practice: Analysis of the implementation of a new guideline for colon cancer
van Rooijen, K. L., Derksen, J. W. G., Verkooijen, H. M., Vink, G. R., & Koopman, M. (2022) · International Journal of Cancer · doi:10.1002/ijc.34149 · Cited by 14
Excessive HSP70/TLR2 activation leads to remodeling of the tumor immune microenvironment to resist chemotherapy sensitivity of mFOLFOX in colorectal cancer
Feng, H., Guo, Z., Chen, X., Liu, K., Li, H., Jia, W., Wang, C., Luo, F., Ji, X., Zhang, T., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109157 · Cited by 16
Low-dose immunogenic chemotherapeutics promotes immune checkpoint blockade in microsatellite stability colon cancer
Fang, Y., Sun, H., Xiao, X., Tang, M., Tian, Z., Wei, H., Sun, R., & Zheng, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1040256 · Cited by 16
Adherence to Clinical Practice Guidelines and Colorectal Cancer Survival: A Retrospective High-Resolution Population-Based Study in Spain
Carrasco-Peña, F., Bayo-Lozano, E., Rodríguez‐Barranco, M., Petrova, D., Marcos‐Gragera, R., Carmona-Garcia, M. C., Borràs, J. M., & Sánchez, M. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17186697 · Cited by 15
Epigenetic insights in the diagnosis, prognosis, and treatment selection in CRC, an updated review
Moghaddam, F. G., Farajnia, S., Karbalaeimahdi, M., & Monir, L. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07569-w · Cited by 14
HIF-1α Expression Increases Preoperative Concurrent Chemoradiotherapy Resistance in Hyperglycemic Rectal Cancer
Huang, Y.-J., Chen, Y., Huang, C., Kuo, S.-H., Liao, Y.-Y., Jhang, W.-Y., Wang, S.-H., Ke, C., Huang, Y.-H., Cheng, C. C., et al. (2022) · Cancers · doi:10.3390/cancers14164053 · Cited by 13
Colorectal Cancer Care in the Age of Coronavirus: Strategies to Reduce Risk and Maintain Benefit
Marshall, J. L., Yarden, R. I., & Weinberg, B. A. (2020) · Colorectal Cancer · doi:10.2217/crc-2020-0010 · Cited by 14
The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy
Iwata, T., Uchino, T., Koyama, A., Johmura, Y., Koyama, K., Saito, T., Ishiguro, S., Arikawa, T., Komatsu, S., Miyachi, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178221 · Cited by 14
Valeur prédictive et pronostique du phénotype MSI dans le cancer du colon non métastatique : qui et comment traiter ?
Zaanan, A., & Taı̈eb, J. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.10.011 · Cited by 15
Neo-adjuvant chemotherapy alone for the locally advanced rectal cancer: a systematic review
Manatakis, D. K., Gouvas, N., Souglakos, J., & Xynos, E. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01738-2 · Cited by 14
Neoadjuvant Chemotherapy without Radiation in Colorectal Cancer
Bhudia, J., Glynne‐Jones, R., Smith, T., & Hall, M. (2020) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0040-1713746 · Cited by 14
The Landmark Series: Chemotherapy for Non-Metastatic Colon Cancer
Alonso, S., & Saltz, L. B. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09375-9 · Cited by 14
Polysaccharides from Chinese herbs as natural weapons against colorectal cancer
Zhou, M., Yue, Y., Wang, Y., & Yan, S. (2023) · Bioscience Reports · doi:10.1042/bsr20230041 · Cited by 13
Oxaliplatin in Adjuvant Colorectal Cancer: Is There a Role in Older Patients?
Dottorini, L., Petrelli, F., Ghidini, A., Rea, C. G., Borgonovo, K., Dognini, G. P., Parati, M. C., Petrò, D., Ghilardi, M., & Luciani, A. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00354 · Cited by 13
Mitochondrial DNA Copy Number as a Biomarker for Guiding Adjuvant Chemotherapy in Stages II and III Colorectal Cancer Patients with Mismatch Repair Deficiency: Seeking Benefits and Avoiding Harms
Chen, M., Deng, S., Cao, Y., Wang, J., Zou, F., Gu, J., Mao, F., Xue, Y., Jiang, Z., Cheng, D., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15759-y · Cited by 13
Clinical importance of DNA repair in sporadic colorectal cancer
Laporte, G. A., Leguisamo, N. M., Kalil, A. N., & Saffi, J. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.017 · Cited by 15
Clinical Implications of Mismatch Repair Status in Patients With High-risk Stage II Colon Cancer
Baek, D. W., Kang, B. W., Lee, S. J., Kim, H. J., Park, S. Y., Park, J. S., Choi, G., Baek, J. H., & Kim, J. G. (2019) · In Vivo · doi:10.21873/invivo.11523 · Cited by 13
Spleen Volume as a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy
Miyata, T., Takamura, H., Kin, R., Nishiki, H., Hashimoto, A., Fujii, Y., Miura, S., Fujita, J., Kaida, D., Tomita, Y., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14319 · Cited by 13
Overexpression of gene DEP domain containing 1 and its clinical prognostic significance in colorectal cancer
Shen, X., & Han, J. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23634 · Cited by 13
High expression of microRNA-126 relates to favorable prognosis for colon cancer patients
Selven, H., Busund, L., Andersen, S., Bremnes, R. M., & Kilvaer, T. K. (2021) · Scientific Reports · doi:10.1038/s41598-021-87985-3 · Cited by 13
The differences on efficacy of oxaliplatin in locally advanced colon cancer between mucinous and nonmucinous adenocarcinoma
Yu, D., Gao, P., Song, Y., Yang, Y., Chen, X., Yu, S. Y., Li, A., & Wang, Z. (2018) · Cancer Medicine · doi:10.1002/cam4.1333 · Cited by 13
Effects of CDX2 on prognosis and chemotherapy responsiveness in mismatch repair-deficient colorectal cancer
Ryan, É. J., Creavin, B., Khaw, Y. L., Kelly, M. E., Mohan, H. M., Geraghty, R., Ryan, E. J., Kennelly, R. P., Hanly, A. M., Martin, S., et al. (2018) · BJS Open · doi:10.1002/bjs5.91 · Cited by 13
Épidémiologie des tumeurs MSI : fréquence des tumeurs MSI en fonction de la localisation du cancer et de son stade
Colle, R., & Cohen, R. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.07.019 · Cited by 13
Multiple High-Risk Features for Stage II Colon Carcinoma Portends Worse Survival Than Stage III Disease
Hajirawala, L. N., Yi, Y., Herritt, B. C., Laurent, M. E., Klinger, A. L., Orangio, G. R., Davis, K. G., & Barton, J. S. (2022) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002425 · Cited by 13
ctDNA to Guide Treatment of Colorectal Cancer: Ready for Standard of Care?
Puccini, A., Martelli, V., Pastorino, A., Sciallero, S., & Sobrero, A. F. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01048-x · Cited by 13
ctDNA-guided adjuvant immunotherapy in colorectal cancer
Burley, N. B., Lee, Y., Liu, L., Gangi, A., Nasseri, Y. Y., Atkins, K. M., Zaghiyan, K. N., Murrell, Z. A., Osipov, A., Hendifar, A. E., et al. (2024) · Immunotherapy · doi:10.1080/1750743x.2024.2430941 · Cited by 12
Identification of an ACK1/TNK2-based prognostic signature for colon cancer to predict survival and inflammatory landscapes
Kong, D., Li, G., Yang, Z., Cheng, S., Zhang, W., Feng, L., & Zhang, K. (2022) · BMC Cancer · doi:10.1186/s12885-021-09165-w · Cited by 12
Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis
Chibaudel, B., Raeisi, M., Cohen, R., Yothers, G., Goldberg, R. M., Bachet, J., Wolmark, N., Yoshino, T., Schmoll, H., Kerr, R. S., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00394 · Cited by 17
Self-citation
Effect of postoperative complications on 5-year survival following laparoscopic surgery for resectable colorectal cancer: a retrospective study
Lee, J. E., Kim, K. E., Jeong, W. K., Baek, S. K., & Bae, S. U. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04730-8 · Cited by 12
Further Evaluating the Benefit of Adjuvant Chemotherapy for Colon Cancer
Sargent, D. J., André, T., & Grothey, A. F. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.4886 · Cited by 12
Self-citation
Clinical Decision Support for High-Risk Stage II Colon Cancer: A Real-World Study of Treatment Concordance and Survival
Chen, P., Li, T., Sun, T., Willis, V. C., Roebuck, M. C., Bravata, D. M., Liu, X.-Z., Arriaga, Y. E., Dankwa‐Mullan, I., & Wu, A. (2020) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001690 · Cited by 12
The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency
Wu, Y., Liu, T., & Hua, Z. (2022) · Cancer Medicine · doi:10.1002/cam4.5076 · Cited by 12
Changing patterns of multidisciplinary team treatment, early mortality, and survival in colorectal cancer
Layfield, D., Flashman, K. G., Majano, S. B., Senapati, A., Ball, C., Conti, J. A., Khan, J. S., & O'Leary, D. P. (2022) · BJS Open · doi:10.1093/bjsopen/zrac098 · Cited by 12
Single nucleotide polymorphisms in genes MACC1, RAD18, MMP7 and SDF-1a as prognostic factors in resectable colorectal cancer
Horvat, M., Potočnik, U., Repnik, K., Kavalar, R., Zadnik, V., Potrč, S., & Štabuc, B. (2016) · Radiology and Oncology · doi:10.1515/raon-2016-0043 · Cited by 12
5-Fluorouracil degradation rate could predict toxicity in stages II–III colorectal cancer patients undergoing adjuvant FOLFOX
Onesti, C. E., Botticelli, A., Torre, M. L., Borro, M., Gentile, G., Romiti, A., Lionetto, L., Petremolo, A., Occhipinti, M. A., Roberto, M., et al. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000453 · Cited by 12
Comparative Analysis of Tumor Cell Dissemination to the Sentinel Lymph Nodes and to the Bone Marrow in Patients With Nonmetastasized Colon Cancer
Weixler, B., Viehl, C. T., Warschkow, R., Güller, U., Ramser, M., Sauter, G., & Zuber, M. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2017.1514 · Cited by 12
Adjuvant Chemotherapy and Tumor Sidedness in Stage II Colon Cancer: Analysis of the National Cancer Data Base
Mukkamalla, S. K. R., Huynh, D. V., Somasundar, P. S., & Rathore, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568417 · Cited by 13
Identification of Hub Genes Associated With Sensitivity of 5-Fluorouracil Based Chemotherapy for Colorectal Cancer by Integrated Bioinformatics Analysis
Wang, Y., Wei, Q., Chen, Y., Long, S., Yao, Y., & Fu, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.604315 · Cited by 12
Accurate Prediction of Prognosis by Integrating Clinical and Molecular Characteristics in Colon Cancer
Wang, L., Su, M., Zhang, M., Zhao, H., Wang, H., Xing, J., Guo, C., Zhou, D., Xue, W., Lu, H., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.664415 · Cited by 12
Hospital‐level compliance with the commission on cancer’s quality of care measures and the association with patient survival
Nussbaum, D. P., Rushing, C. N., Sun, Z., Yerokun, B. A., Worni, M., Saunders, R. S., McClellan, M., Niedzwiecki, D., Greenup, R. A., & Blazer, D. G. (2021) · Cancer Medicine · doi:10.1002/cam4.3875 · Cited by 11
Lymph Node Metastases and Associated Recurrence-Free Survival in Microsatellite Stable and Unstable Colon Cancer
Hakki, L., Khan, A., Gönen, M., Stadler, Z. K., Segal, N. H., Shia, J., Widmar, M., Wei, I. H., Smith, J. J., Pappou, E. P., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14270-0 · Cited by 11
Molecular features and prognostic factors of locally advanced microsatellite instability-high gastric cancer
Furukawa, K., Hatakeyama, K., Terashima, M., Urakami, K., Koseki, Y., Fujiya, K., Tanizawa, Y., Bando, E., & Yamaguchi, K. D. (2024) · Gastric Cancer · doi:10.1007/s10120-024-01506-5 · Cited by 11
Introducing Neoadjuvant Immunotherapy for Colorectal Cancer
Orhan, A., Justesen, T. F., Raskov, H., Qvortrup, C., & Gögenür, I. (2024) · Annals of Surgery · doi:10.1097/sla.0000000000006443 · Cited by 13
Colon cancer biology and treatment in the era of precision oncology: A primer for Radiologists
Platt, J. R., Pennycook, S., Muthoo, C., Westwood, A. C., Frood, R. T., Beggs, A. D., Scarsbrook, A. F., Seligmann, J. F., & Tolan, D. J. M. (2025) · European Journal of Radiology · doi:10.1016/j.ejrad.2025.112000 · Cited by 12
Age Determines Adjuvant Chemotherapy Use in Resected Stage II Colon Cancer
Hagerty, B. L., Aversa, J. G., Dominguez, D. A., Davis, J. L., Hernandez, J. M., McCormick, J. T., & Blakely, A. M. (2021) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002074 · Cited by 11
Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
Khalil, L. E., Gao, X., Switchenko, J. M., Alese, O. B., Akce, M., Wu, C. S.-Y., Diab, M., El‐Rayes, B. F., & Shaib, W. L. (2022) · The Oncologist · doi:10.1093/oncolo/oyac082 · Cited by 11
Predictive Value of Circulating Tumor Cells Based on Subtraction Enrichment for Recurrence Risk in Stage II Colorectal Cancer
Chen, L., Zhou, W., Ye, Z., Zhong, X., Zhou, J., Chen, S., Liu, W., Sun, Y., Ren, L., Tan, X., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c08560 · Cited by 11
Integrative Clinical and DNA Methylation Analyses in a Population-Based Cohort Identifies CDH17 and LRP2 as Risk Recurrence Factors in Stage II Colon Cancer
Tournier, B., Aucagne, R., Truntzer, C., Fournier, C., Ghiringhelli, F., Chapusot, C., Martin, L., Bouvier, A., Manfrédi, S., Jooste, V., et al. (2022) · Cancers · doi:10.3390/cancers15010158 · Cited by 11

Mosaic Study: Actualization of Overall Survival (Os) with 10 Years Follow Up and Evaluation of Braf. By Gercor and Mosaic Investigators
André, T., de Gramont, A., Chibaudel, B., Tijeras‐Raballand, A., Duval, A., Hickish, T., Tabernero, J. M., Laethem, J. V., Banzi, M. C., Maartense, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu333.5 · Cited by 3
Self-citation
Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study.
Fléjou, J., André, T., Chibaudel, B., Scriva, A., Hickish, T., Tabernero, J. M., Laethem, J. V., Banzi, M. C., Maartense, E., Shani, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3524 · Cited by 23
Self-citation
Prognostic Effect ofBRAFandKRASMutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab
Taı̈eb, J., Zaanan, A., Malicot, K. L., Julié, C., Blons, H., Mineur, L., Bennouna, J., Tabernero, J. M., Mini, E., Folprecht, G., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5225 · Cited by 164
Self-citation
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
André, T., Boni, C., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Bonetti, A. V., Clingan, P. R., Bridgewater, J. A., Rivera, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6771 · Cited by 2,276
Self-citation
Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy
Sinicrope, F. A., Mahoney, M. R., Smyrk, T. C., Thibodeau, S. N., Warren, R. S., Bertagnolli, M. M., Nelson, G. D., Goldberg, R. M., Sargent, D. J., & Alberts, S. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.9591 · Cited by 285

See all

Authors: André, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., Scriva, A., Hickish, T., Tabernero, J., Van Laethem, J. L., Banzi, M., Maartense, E., Shmueli, E., Carlsson, G. U., Scheithauer, W., Papamichael, D., Möehler, M., Landolfi, S., Demetter, P., Colote, S., Tournigand, C., Louvet, C., Duval, A., Fléjou, J.-F., & de Gramont, A.
Affiliations: Inserm (FR)
Thierry André and Jean-François Fléjou, Hôpital St Antoine; Thierry André and Jean-François Fléjou, University Pierre et Marie Curie Paris VI; Thierry André, Benoist Chibaudel, Annemilaï Tijeras-Raballand, Soudhir Colote, and Aimery de Gramont, Groupe Coopérateur Multdisciplinaire en Ocologie (GERCOR) Oncology Multidisciplinary Group and GERCOR-Innovative Research Consortium; Christophe Louvet, Institut Mutualiste Montsouris; Alex Duval, L'Institut National de la Santé et de la Recherche Médicale UMRS...
ORCID: André, Thierry
Chibaudel, Benoist
Hickish, Tamas
Tabernero, Josep
Banzi, Maria
Shmueli, Einat
Papamichael, Demetris
Landolfi, Stefania
Demetter, Pieter
Tournigand, Christophe
Louvet, Christophe
Duval, Alex
Fléjou, Jean-François
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2015-12-10
Volume: 33
Issue: 35
Pages: 4176-4187
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2015.63.4238
OpenAlex: W1960485012
Cited by: 683
References: 32
Citations by year: 2026: 43 · 2025: 56 · 2024: 75 · 2023: 65 · 2022: 74 · 2021: 92 · 2020: 97 · 2019: 47 · 2018: 59 · 2017: 41 · 2016: 32
FWCI: 19.22
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
IRIS (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Funders: European Society for Medical Oncology
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: colon cancer, adjuvant chemotherapy, oxaliplatin, FOLFOX4, 5-fluorouracil, leucovorin, BRAF mutation, mismatch repair deficiency, overall survival, disease-free survival, prognostic factors, stage II colon cancer, stage III colon cancer, mosaic studies, long-term follow-up, microsatellite instability, mismatch repair proteins
MeSH terms: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Colonic Neoplasms, Female, Fluorouracil, Follow-Up Studies, Humans, Infusions, Intravenous, Injections, Intravenous, Male, Middle Aged, Mutation, Neoplasm Staging, Organoplatinum Compounds, Prognosis, Valine, Odds Ratio, Treatment Outcome, Chemotherapy, Adjuvant, Disease-Free Survival, Glutamic Acid, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate, DNA Mismatch Repair

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks